News Articles and Montana BioScience Alliance Newsletters
A Montana State University undergraduate has been admitted to a prestigious European graduate program where she will advance her research in disease prevention and other applications of the growing field of bioinformatics.
Beginning with cannabis, the Missoula, MT based company is creating a self-contained and portable product that can detect impairment in real-time. The product will be sold to law enforcement agencies, and businesses with safety-critical employees.
Tonix Pharmaceuticals will collaborate with Massachusetts General Hospital to further develop a humanized monoclonal antibody, TNX-1500, to prevent organ transplant rejection, specifically in kidney transplants.
Potential Uses Include: Biomarker of Immunity to SARS-CoV-2; Personalized Approach to Timing COVID-19 Vaccine Boosters; Public Health Surveillance; and Serving as an Endpoint for COVID-19 Vaccine Trials
Their ideas included a virtual reality textbook, a new building material, a food incubator, a device to assist construction workers, various software solutions and a student-focused professional networking platform.
When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.
View the Spring 2024 Newsletter Newsletter now!
View the Winter II 2024 Newsletter now!